

Date: 31 October 2025

Ref. No.: TCPCL/SEC/2025-26/00052

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Tatva Chintan Pharma Chem Limited (the "Company") in its meeting held today i.e. 31 October 2025 have *inter-alia*, approved and taken on record the following items:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2025. In this regard, please find enclosed:
 - i. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2025; and
 - ii. Limited Review Report (Standalone and Consolidated) for the quarter and half year ended 30 September 2025, issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company.
2. The Board, based on the recommendation of Nomination and Remuneration Committee and Audit Committee, has approved the appointment of Mr. Ajesh Kumar Mohanan Pillai as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from 31 October 2025.

Disclosure under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 for matters mentioned at Item 2, is enclosed herewith as "**Annexure A**".

The above information shall be made available on the website of the Company at www.tatvachintan.com.

The Meeting commenced at 11:30 A.M. and concluded at 03:40 P.M.

Kindly take above intimation on your record and oblige.

Thanking you,

Yours faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above

Disclosure under Regulation 30 of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.

Annexure A

Sr. No.	Particulars	Mr. Ajesh Kumar Mohanan Pillai (Chief Financial Officer)
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Chief Financial Officer (CFO) and Key Managerial Officer (KMP) of the Company.
2.	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment	Appointment is with effect from 31 October 2025.
3.	Brief profile (in case of appointment)	Mr. Ajesh Kumar Mohanan Pillai brings over two decades of leadership experience in finance, accounts, and strategic management across diverse industries. Being a Commerce graduate and Certified Forensic Accountant and Fraud Investigator, he has demonstrated deep expertise in financial planning, governance, and operational excellence throughout his career. Associated with Tatva Chintan Pharma Chem Limited for more than 10 years, Mr. Pillai has played an instrumental role in strengthening the company's financial systems, internal controls, and strategic decision making frameworks. Over the years, he has led critical initiatives in budgeting, capital planning, treasury management, and ERP implementation, contributing significantly to the company's growth and process modernization. In his previous roles as Head – Accounts and Finance, and most recently as Executive Assistant to the Director and Investor Relations Officer, Mr. Pillai has demonstrated strong business acumen, analytical depth, and effective stakeholder communication - bridging financial insight with strategic execution. A skilled communicator, technology driven finance professional and an impactful administrator, Mr. Pillai is known for his ability to align financial strategies with long-term business goals, enhance transparency, and foster cross-functional collaboration. His leadership experience across various companies and industries continues to play a pivotal role in driving Tatva Chintan's next phase of growth and value creation.
4.	Disclosure of Relationship between Directors (in case of appointment as a Director)	Not Applicable
5.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, both dated 20 June 2018	Not Applicable

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Tatva Chintan Pharma Chem Limited ("Holding Company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2025 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the following entities:
 - a) Tatva Chintan Pharma Chem Limited – the Holding Company
 - b) Tatva Chintan USA Inc. – Wholly Owned Subsidiary
 - c) Tatva Chintan Europe B.V. – Wholly Owned Subsidiary



6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W



CA Basant Chandak
Partner

Membership No.: 434585

UDIN No.: 25434585BMITEL1905

Date: 31 October 2025

Place: Vadodara





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Financial Results

for the quarter and half year ended 30 September 2025

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
	Income						
1	Revenue from operations	1,235.16	1,168.64	834.90	2,403.80	1,889.54	3,827.14
2	Other income	10.08	11.55	3.77	21.63	15.50	23.15
3	Total income (1+2)	1,245.24	1,180.19	838.67	2,425.43	1,905.04	3,850.29
	Expenses						
	Cost of materials consumed	619.87	638.89	392.87	1,258.76	808.09	1,737.64
	Purchases of stock-in-trade	12.38	12.89	5.32	25.27	10.75	29.80
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(83.63)	(68.32)	29.02	(151.95)	178.36	221.97
	Employee benefits expense	149.47	140.86	129.39	290.33	256.34	529.16
	Finance costs	5.07	4.13	1.72	9.20	4.86	12.90
	Depreciation and amortisation expenses	90.53	89.71	68.13	180.24	134.78	276.59
	Other expenses	314.92	271.02	222.43	585.94	453.98	966.44
4	Total expenses	1,108.61	1,089.18	848.88	2,197.79	1,847.16	3,774.50
5	Profit/(loss) before exceptional items and tax (3-4)	136.63	91.01	(10.21)	227.64	57.88	75.79
6	Exceptional items	-	-	-	-	-	-
7	Profit/(loss) before tax (5-6)	136.63	91.01	(10.21)	227.64	57.88	75.79
	Tax expenses/(benefits)						
	Current tax	24.80	18.62	(1.73)	43.42	7.54	15.47
	Deferred tax	12.66	5.88	(1.84)	18.54	4.89	3.19
8	Total tax expenses/(benefits)	37.46	24.50	(3.57)	61.96	12.43	18.66
9	Profit/(loss) for the period/year (7-8)	99.17	66.51	(6.64)	165.68	45.45	57.13
	Other comprehensive income/(expense)						
	Items that will not be reclassified to profit or loss	(0.98)	(0.98)	(0.75)	(1.96)	(1.50)	(3.06)
	Income tax relating to items that will not be reclassified to profit or loss	0.29	0.28	0.22	0.57	0.44	0.89
	Items that will be reclassified to profit or loss	7.94	6.80	(2.55)	14.74	7.62	9.24
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
10	Other comprehensive income/(expense) for the period/year, net of tax	7.25	6.10	(3.08)	13.35	6.56	7.07
11	Total comprehensive income/(expense) for the period/year (9+10)	106.42	72.61	(9.72)	179.03	52.01	64.20
12	Profit/(loss) for the period/year attributable to:						
	- Owners of the parent	99.17	66.51	(6.64)	165.68	45.45	57.13
	- Non controlling interests	-	-	-	-	-	-
		99.17	66.51	(6.64)	165.68	45.45	57.13
13	Other comprehensive income/(expense) for the period/year attributable to:						
	- Owners of the parent	7.25	6.10	(3.08)	13.35	6.56	7.07
	- Non controlling interests	-	-	-	-	-	-
		7.25	6.10	(3.08)	13.35	6.56	7.07
14	Total comprehensive income/(expense) for the period/year attributable to:						
	- Owners of the parent	106.42	72.61	(9.72)	179.03	52.01	64.20
	- Non controlling interests	-	-	-	-	-	-
		106.42	72.61	(9.72)	179.03	52.01	64.20
15	Earnings per share						
	(Face value of Rs 10/- each) (not annualised)						
	- Basic	4.24	2.84	(0.29)	7.08	1.94	2.44
	- Diluted	4.24	2.84	(0.29)	7.08	1.94	2.44
16	Paid - up equity share capital	233.92	233.92	233.92	233.92	233.92	233.92
	(Face value of Rs 10/- each)						
17	Other equity excluding revaluation reserve						7,154.32

Notes forming part of the consolidated statement of financial results





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Assets and Liabilities

as at 30 September 2025

(Currency: Indian Rupees in million)

Particulars	30.09.2025 (Unaudited)	31.03.2025 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	4,796.85	4,959.96
Right-of-use assets	293.25	295.56
Capital work-in-progress	798.80	215.35
Other intangible assets	53.13	31.24
Intangible assets under development	11.51	27.75
Financial assets		
i) Other financial assets	42.12	42.82
Deferred tax assets (net)	108.28	126.24
Other non-current assets	9.03	11.12
Total non-current assets	6,112.97	5,710.04
Current assets		
Inventories	1,460.37	1,339.54
Financial assets		
i) Trade receivables	1,014.10	825.27
ii) Cash and cash equivalents	125.38	113.74
iii) Bank balances other than cash and cash equivalents	46.34	27.22
iv) Loans	2.09	2.37
v) Other financial assets	6.75	11.01
Current tax assets (net)	76.97	61.17
Other current assets	232.43	263.60
Total current assets	2,964.43	2,643.92
Total assets	9,077.40	8,353.96
EQUITY AND LIABILITIES		
Equity		
Equity share capital	233.92	233.92
Other equity	7,309.97	7,154.32
Equity attributable to owners	7,543.89	7,388.24
Non-controlling interests	-	-
Total equity	7,543.89	7,388.24
Liabilities		
Non-current liabilities		
Provisions	13.98	13.98
Total non-current liabilities	13.98	13.98
Current liabilities		
Financial liabilities		
i) Borrowings	830.13	363.88
ii) Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	122.20	108.21
(b) total outstanding dues of creditors other than above	236.91	218.68
iii) Other financial liabilities	123.84	54.69
Other current liabilities	189.85	190.41
Provisions	4.66	4.24
Current tax liabilities (net)	11.94	11.63
Total current liabilities	1,519.53	951.74
Total equity and liabilities	9,077.40	8,353.96

Notes forming part of the consolidated financial results

1- 8





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Cash Flows

for the half year ended 30 September 2025

(Currency: Indian Rupees in million)

Particulars	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
A. Cash flows from operating activities:			
Profit before tax (i)	227.64	57.88	75.79
Adjustments to reconcile profit:			
Finance costs	9.20	4.86	12.90
Depreciation and amortisation expenses	180.24	134.78	276.59
Unrealised foreign exchange loss/(gain) (net)	4.26	0.32	(0.24)
Interest income	(1.27)	(1.86)	(4.87)
Net gain on sale of current investments	(0.06)	(0.75)	(0.75)
Other non-cash items	14.91	7.48	9.47
Total adjustments to reconcile profit (ii)	207.28	144.83	293.10
Operating profit before working capital changes (iii) = (i) + (ii)	434.92	202.71	368.89
Changes in working capital:			
(Increase)/decrease in inventories	(120.83)	82.83	188.11
(Increase)/decrease in trade receivables	(153.98)	26.34	(151.62)
Decrease/(increase) in other non-current financial assets	0.70	0.41	(0.22)
Decrease/(increase) in other current financial assets	4.27	1.35	(0.66)
Decrease/(increase) in other non-current assets	2.09	(4.66)	(2.80)
Decrease/(increase) in other current assets	1.28	(13.34)	(61.74)
Increase/(decrease) in trade payables	43.79	(176.64)	(131.05)
(Decrease)/increase in other current financial liabilities	(3.59)	0.12	0.04
Increase in other current liabilities	(17.33)	51.14	81.48
Increase in non-current provisions	-	-	0.64
Increase in current provisions	0.42	0.14	0.62
Total changes in working capital (iv)	(243.18)	(32.31)	(77.20)
Cash generated from operating activities (v) = (iii) + (iv)	191.74	170.40	291.69
Less: Taxes paid (vi)	(57.93)	(47.43)	(44.98)
Net cash generated from operating activities (A) = (v) + (vi)	133.81	122.97	246.71
B. Cash flows from investing activities:			
Purchase of property, plant and equipment (including right-of-use assets, capital work-in-progress, other intangible assets and intangible assets under development.)	(559.99)	(421.11)	(762.72)
Proceeds from sale of property, plant and equipment	0.03	0.36	1.39
(Increase)/decrease in deposits with banks	(19.13)	3.30	2.65
Purchase of current investment	(40.01)	-	-
Proceeds from sale of current investments	40.07	101.27	101.27
Interest income	1.27	1.86	4.87
Cash (used in) investing activities (B)	(577.76)	(314.32)	(652.54)





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Cash Flows

for the half year ended 30 September 2025

(Currency: Indian Rupees in million)

Particulars	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
C. Cash flows from financing activities:			
Dividend paid	-	(46.78)	(46.78)
Repayment of long-term borrowings	(4.43)	(22.70)	(32.19)
Net proceeds from short-term borrowings	470.68	35.43	257.49
Decrease in loans to employees	0.27	0.92	0.04
Finance costs	(9.20)	(4.86)	(12.90)
Cash generated from/(used in) financing activities (C)	457.32	(37.99)	165.66
Net increase/(decrease) in cash and cash equivalents D=(A+B+C)	13.37	(229.34)	(240.17)
Cash and cash equivalents at the beginning of the year (E)	113.74	353.04	353.04
Effect of exchange rate changes on cash and cash equivalents (F)	(1.73)	(1.55)	0.87
Cash and cash equivalents at the end of the year (D+E+F)	125.38	122.15	113.74
Components of cash and cash equivalents:			
Cash on hand	0.87	0.82	0.82
Balances with banks:			
- in current accounts	0.63	33.81	6.30
- in current accounts (foreign currency)	33.66	35.74	21.69
- in cash credit accounts (surplus)	-	2.25	0.01
- in EEFC current accounts	85.40	45.06	80.35
- in deposits with original maturity of less than 3 months	4.82	4.47	4.57
Balance as per statement of cash flows	125.38	122.15	113.74

Notes forming part of the consolidated statement of financial results

1- 8





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Consolidated Statement of Financial Results

for the quarter and half year ended 30 September 2025


(Currency: Indian Rupees in million)


- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Consolidated Financial Results for the quarter and half year ended 30 September 2025 ("Consolidated Financial Results") of Tatva Chintan Pharma Chem Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group" or "the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 31 October 2025.
- The Consolidated Financial Results of the Company for the quarter and half year ended 30 September 2025, has been subjected to limited review by the statutory auditors of the Company, who has expressed an unmodified opinion.
- The Consolidated Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- The Consolidated Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of cash flows.
- Key numbers of Standalone Statement of Financial Results for the quarter and half year ended 30 September 2025:

Sr. no.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
1.	Total income from operations (Net)	1,158.63	1,091.80	809.60	2,250.43	1,747.68	3,664.15
2.	Net profit/(loss) before tax (before exceptional items)	123.43	70.54	(15.77)	193.97	5.60	4.61
3.	Net profit/(loss) before tax (after exceptional items)	123.43	70.54	(15.77)	193.97	5.60	4.61
4.	Net profit/(loss) after tax	89.41	51.33	(11.11)	140.74	3.97	3.27
5.	Total comprehensive income/(expense)	88.72	50.63	(11.64)	139.35	2.91	1.10

- The Consolidated Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on Company's website www.tatvachintan.com.
- Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited


Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 31 October 2025



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Tatva Chintan Pharma Chem Limited ("the Company") for the quarter and half year ended 30th September 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W



CA Basant Chandak

Partner

Membership No.: 434585

UDIN No.: 25434585BMITEK5830

Date: 31 October 2025

Place: Vadodara





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Financial Results

for the quarter and half year ended 30 September 2025

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2025 (Unaudited)	30.06.2025 (Unaudited)	30.09.2024 (Unaudited)	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
	Income						
1	Revenue from operations	1,158.63	1,091.80	809.60	2,250.43	1,747.68	3,664.15
2	Other income	7.94	13.69	8.06	21.63	22.26	35.61
3	Total income (1+2)	1,166.57	1,105.49	817.66	2,272.06	1,769.94	3,699.76
	Expenses						
	Cost of materials consumed	619.87	638.89	392.87	1,258.76	808.09	1,737.64
	Purchases of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods and work-in-progress	(103.22)	(89.20)	34.81	(192.42)	139.86	239.01
	Employee benefits expense	149.47	140.86	129.39	290.33	256.34	529.16
	Finance costs	5.07	4.13	1.72	9.20	4.86	12.90
	Depreciation and amortisation expense	90.53	89.69	68.11	180.22	134.75	276.54
	Other expenses	281.42	250.58	206.53	532.00	420.44	899.90
4	Total expenses	1,043.14	1,034.95	833.43	2,078.09	1,764.34	3,695.15
5	Profit/(loss) before exceptional items and tax (3-4)	123.43	70.54	(15.77)	193.97	5.60	4.61
6	Exceptional items	-	-	-	-	-	-
7	Profit/(loss) before tax (5-6)	123.43	70.54	(15.77)	193.97	5.60	4.61
	Tax expenses/(benefits)						
	Current tax	21.43	12.12	(2.88)	33.55	0.72	0.02
	Deferred tax	12.59	7.09	(1.78)	19.68	0.91	1.32
8	Total tax expenses/(benefits)	34.02	19.21	(4.66)	53.23	1.63	1.34
9	Profit/(loss) for the period/year (7-8)	89.41	51.33	(11.11)	140.74	3.97	3.27
	Other comprehensive income/(expenses)						
	Items that will not be reclassified to profit or loss	(0.98)	(0.98)	(0.75)	(1.96)	(1.50)	(3.06)
	Income tax relating to items that will not be reclassified to profit or loss	0.29	0.28	0.22	0.57	0.44	0.89
10	Other comprehensive (expenses) for the period/year, net of tax	(0.69)	(0.70)	(0.53)	(1.39)	(1.06)	(2.17)
11	Total comprehensive income/(expense) for the period/year (9+10)	88.72	50.63	(11.64)	139.35	2.91	1.10
12	Earnings per share (Face value of Rs 10/- each) (not annualised)						
	- Basic	3.82	2.19	(0.47)	6.01	0.17	0.14
	- Diluted	3.82	2.19	(0.47)	6.01	0.17	0.14
13	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92	233.92	233.92
14	Other equity excluding revaluation reserve						6,979.20

Notes forming part of the standalone statement of financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Assets and Liabilities

as at 30 September 2025

(Currency: Indian Rupees in million)

Particulars	30.09.2025 (Unaudited)	31.03.2025 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	4,796.71	4,959.80
Right-of-use assets	293.25	295.56
Capital work-in-progress	798.80	215.35
Other intangible assets	53.13	31.24
Intangible assets under development	11.51	27.75
Financial assets		
i) Investments	6.67	6.67
ii) Other financial assets	42.12	42.82
Deferred tax assets (net)	103.43	122.54
Other non-current assets	9.03	11.12
Total non-current assets	6,114.65	5,712.85
Current assets		
Inventories	1,384.84	1,233.01
Financial assets		
i) Trade receivables	905.46	761.60
ii) Cash and cash equivalents	91.73	92.05
iii) Bank balances other than cash and cash equivalents	46.34	27.22
iv) Loans	2.09	2.37
v) Other financial assets	6.75	11.01
Current tax assets (net)	58.67	54.82
Other current assets	445.76	333.08
Total current assets	2,941.64	2,515.16
Total assets	9,056.29	8,228.01
EQUITY AND LIABILITIES		
Equity		
Equity share capital	233.92	233.92
Other equity	7,095.16	6,979.20
Total equity	7,329.08	7,213.12
Liabilities		
Non-current liabilities		
Provisions	13.98	13.98
Total non-current liabilities	13.98	13.98
Current liabilities		
Financial liabilities		
i) Borrowings	830.13	363.88
ii) Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	122.20	108.21
(b) total outstanding dues of creditors other than above	232.18	214.88
iii) Other financial liabilities	123.84	54.69
Other current liabilities	400.22	255.01
Provisions	4.66	4.24
Total current liabilities	1,713.23	1,000.91
Total equity and liabilities	9,056.29	8,228.01

Notes forming part of the standalone statement of financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Cash Flows

for the half year ended 30 September 2025

(Currency: Indian Rupees in million)

Particulars	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
A. Cash flows from operating activities:			
Profit before tax (i)	193.97	5.60	4.61
Adjustments to reconcile profit:			
Finance costs	9.20	4.86	12.90
Depreciation and amortisation expenses	180.22	134.75	276.54
Unrealised foreign exchange loss/(gain) (net)	4.66	(0.59)	(0.67)
Interest income	(1.27)	(1.86)	(4.87)
Net gain on sale of current investments	(0.06)	(0.75)	(0.75)
Other non-cash items	0.17	(0.13)	0.23
Total adjustments to reconcile profit (ii)	192.92	136.28	283.38
Operating profit before working capital changes (iii) = (i) + (ii)	386.89	141.88	287.99
Changes in working capital:			
(Increase)/decrease in inventories	(151.82)	45.77	208.08
(Increase)/decrease in trade receivables	(110.75)	95.49	(100.85)
Decrease/(increase) in other non-current financial assets	0.70	0.41	(0.22)
Decrease/(increase) in other current financial assets	4.27	1.35	(0.66)
Decrease/(increase) in other non-current assets	2.09	(4.66)	(2.80)
(Increase) in other current assets	(142.46)	(44.38)	(39.51)
Increase/(decrease) in trade payables	42.50	(173.47)	(129.06)
(Decrease)/increase in other current financial liabilities	(3.59)	0.12	0.04
Increase in other current liabilities	128.41	82.10	59.15
Increase in non-current provisions	-	-	0.64
Increase in current provisions	0.42	0.14	0.62
Total changes in working capital (iv)	(230.23)	2.87	(4.57)
Cash generated from operating activities (v) = (iii) + (iv)	156.66	144.75	283.42
Less: Taxes paid (vi)	(36.54)	(45.90)	(44.37)
Net cash generated from operating activities (A) = (v) + (vi)	120.12	98.85	239.05
B. Cash flows from investing activities:			
Purchase of property, plant and equipment (including right-of-use assets, capital work-in-progress, other intangible assets and intangible assets under development.)	(559.99)	(421.10)	(762.70)
Proceeds from sale of property, plant and equipment	0.03	0.36	1.39
(Increase)/decrease in deposits with banks	(19.13)	3.30	2.65
Purchase of current investment	(40.01)	-	-
Proceeds from sale of current investments	40.07	101.27	101.27
Interest income	1.27	1.86	4.87
Cash (used in) investing activities (B)	(577.76)	(314.31)	(652.52)





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91-75748 48533

Standalone Statement of Cash Flows


for the half year ended 30 September 2025

(Currency: Indian Rupees in million)

Particulars	30.09.2025 (Unaudited)	30.09.2024 (Unaudited)	31.03.2025 (Audited)
C. Cash flows from financing activities:			
Dividend paid	-	(46.78)	(46.78)
Repayment of long-term borrowings	(4.43)	(22.70)	(32.19)
Net proceeds from short-term borrowings	470.68	35.43	257.49
Decrease in loans to employees	0.27	0.92	0.04
Finance costs	(9.20)	(4.86)	(12.90)
Cash generated from/(used in) financing activities (C)	457.32	(37.99)	165.66
Net (decrease) in cash and cash equivalents D=(A+B+C)	(0.32)	(253.45)	(247.81)
Cash and cash equivalents at the beginning of the year (E)	92.05	339.86	339.86
Effect of exchange rate changes on cash and cash equivalents (F)	0.00	(0.01)	(0.00)
Cash and cash equivalents at the end of the year (D+E+F)	91.73	86.40	92.05
Components of cash and cash equivalents:			
Cash on hand	0.87	0.82	0.82
Balances with banks:			
- in current accounts	0.64	33.80	6.30
- in cash credit accounts (surplus)	-	2.25	0.01
- in EEFC current accounts	85.40	45.06	80.35
- in deposits with original maturity of less than 3 months	4.82	4.47	4.57
Balance as per statement of cash flows	91.73	86.40	92.05

Notes forming part of the standalone statement of financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Standalone Statement of Financial Results

for the quarter and half year ended 30 September 2025

(Currency: Indian Rupees in million)

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Standalone Financial Results for the quarter and half year ended 30 September 2025 ("Standalone Financial Results") of Tatva Chintan Pharma Chem Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 31 October 2025.
- 2 The Standalone Financial Results of the Company for the quarter and half year ended 30 September 2025, has been subjected to limited review by the statutory auditors of the Company, who has expressed an unmodified opinion.
- 3 The Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- 5 The Standalone Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS-7) - Statement of cash flows.
- 6 The Standalone Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on Company's website www.tatvachintan.com.
- 7 Figures for the previous periods/year have been re-classified/re-arranged/re-grouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited

Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 31 October 2025

